Chris R Triggle
Overview
Explore the profile of Chris R Triggle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
2202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sarkar A, Fanous K, Marei I, Ding H, Ladjimi M, MacDonald R, et al.
Vasc Health Risk Manag
. 2024 Jun;
20:255-288.
PMID: 38919471
Metformin is an orally effective anti-hyperglycemic drug that despite being introduced over 60 years ago is still utilized by an estimated 120 to 150 million people worldwide for the treatment...
2.
Samuel S, Varghese E, Satheesh N, Triggle C, Busselberg D
Biomed Pharmacother
. 2023 May;
164:114911.
PMID: 37224753
Breast cancers (BCs) remain the leading cause of cancer-related deaths among women worldwide. Among the different types of BCs, treating the highly aggressive, invasive, and metastatic triple-negative BCs (TNBCs) that...
3.
Marei I, Ahmetaj-Shala B, Triggle C
Front Pharmacol
. 2022 Oct;
13:982185.
PMID: 36299902
Stent thrombosis remains one of the main causes that lead to vascular stent failure in patients undergoing percutaneous coronary intervention (PCI). Type 2 diabetes mellitus is accompanied by endothelial dysfunction...
4.
Triggle C, Marei I, Ye K, Ding H, Anderson T, Hollenberg M, et al.
Curr Med Chem
. 2022 Aug;
30(35):3955-3978.
PMID: 35909294
Metformin has been used as an oral anti-hyperglycaemic drug since the late 1950s; however, following the release in 1998 of the findings of the 20-year United Kingdom Prospective Diabetes Study...
5.
Triggle C, Mohammed I, Bshesh K, Marei I, Ye K, Ding H, et al.
Metabolism
. 2022 May;
133:155223.
PMID: 35640743
Metformin was first used to treat type 2 diabetes in the late 1950s and in 2022 remains the first-choice drug used daily by approximately 150 million people. An accumulation of...
6.
Samuel S, Varghese E, Triggle C, Busselberg D
Vaccines (Basel)
. 2022 Mar;
10(3).
PMID: 35335086
The COVID-19 vaccines currently in use have undoubtedly played the most significant role in combating the SARS-CoV-2 virus and reducing disease severity and the risk of death among those affected,...
7.
Suhre K, Stephan N, Zaghlool S, Triggle C, Robinson R, Evans A, et al.
Metabolites
. 2022 Mar;
12(3).
PMID: 35323692
Modern metabolomics platforms are able to identify many drug-related metabolites in blood samples. Applied to population-based biobank studies, the detection of drug metabolites can then be used as a proxy...
8.
Marei I, Abu Samaan T, Al-Quradaghi M, Farah A, Mahmud S, Ding H, et al.
Front Cardiovasc Med
. 2022 Mar;
9:847554.
PMID: 35310996
Despite the efforts devoted to drug discovery and development, the number of new drug approvals have been decreasing. Specifically, cardiovascular developments have been showing amongst the lowest levels of approvals....
9.
Venu V, Saifeddine M, Mihara K, Faiza M, Gorobets E, Flewelling A, et al.
Mol Pharmacol
. 2021 Aug;
100(5):428-455.
PMID: 34452975
Vascular pathology is increased in diabetes because of reactive-oxygen-species (ROS)-induced endothelial cell damage. We found that and in a streptozotocin diabetes model , metformin at diabetes-therapeutic concentrations (1-50 µM) protects...
10.
Mohammed I, Hollenberg M, Ding H, Triggle C
Front Endocrinol (Lausanne)
. 2021 Aug;
12:718942.
PMID: 34421827
The numerous beneficial health outcomes associated with the use of metformin to treat patients with type 2 diabetes (T2DM), together with data from pre-clinical studies in animals including the nematode,...